Enhancing anti-tumor response in melanoma cells with defective sting signaling

Inventors

Mulé, James • Falahat, Rana • Barber, Glen

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Assignees

Moffitt Cancer Center

Member
University of Miami
University of Miami

The University of Miami, established in 1925 and based in Coral Gables, Florida, is a private research university recognized for its comprehensive academic offerings, robust research infrastructure, and strong interdisciplinary focus. Home to more than 19,000 students and with more than 400 acres of campuses across the Miami region, its mission encompasses education, research, innovation, and community service. The institution supports clinical, biomedical, marine, and atmospheric research initiatives, delivers diverse undergraduate and graduate programs, and maintains numerous research centers and institutes dedicated to scientific, medical, and societal advancements.

Publication Number

US-12584919-B2

Patent

Publication Date

2026-03-24

Expiration Date


Abstract

Disclosed herein is a method for enhancing antitumor T cell responses in subjects. The method involves administering to the subject in need thereof a composition comprising a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. This method is particularly useful in subjects with deficient STING expression in the tumor cells. Therefore, also disclosed is a method for treating a tumor in a subject that involves detecting in a biopsy sample from the subject reduced STING expression, reduced cGAS expression, or a combination thereof; and then administering to the subject a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. The method can further involve administering to the subject a therapeutically effective amount of a STING agonist. The method can further involve administering to the subject tumor infiltrating lymphocytes (TILs), such as HLA-matched TILs.

Core Innovation

The invention relates to producing enhanced tumor infiltrating lymphocytes (TILs) by increasing tumor-cell STING and/or cGAS signaling through epigenetic modulation. It links DNA methylation in STING/cGAS regulatory regions to reduced STING expression and reduced cGAS expression in tumor cells, including melanoma cell lines with defective STING signaling. The disclosed approach uses a demethylating agent to increase STING expression in tumor cells.

The invention further combines demethylation with administration of a STING agonist to increase the antigenicity of treated tumor cells. In the disclosed workflow, tumor cells are cultured in the presence of a demethylating agent and a STING agonist, and then TILs are co-cultured with these treated tumor cells followed by further expanding the TILs after their exposure. The method uses demethylation and STING agonist signaling together to enhance the immunologic interaction between tumor cells and TILs.

The disclosed embodiments optionally include subject-based screening and selection elements based on biomarkers in tumor biopsies. The document describes assaying a subject’s biopsy sample for STING expression, cGAS expression, DNA methylation, and/or methylation in regulatory regions of STING and/or cGAS prior to treatment. The results are linked to STING-dependent signaling outcomes including induction of CXCL10 and IFN-β, increased MHC-I (HLA-A/B/C) expression, enhanced HLA-restricted TIL effector functions, and tumor immune cell recruitment through CXCR3-binding chemokines.

Claims Coverage

The document provides two independent claims that both define methods for producing enhanced tumor infiltrating lymphocytes (TILs). The independent claim set includes two complementary workflows: culturing tumor cells with a demethylating agent and a STING agonist followed by co-culture and expansion of TILs, and treating a subject to increase STING expression in tumor cells, then isolating and culturing tumor cells with a STING agonist followed by co-culture and expansion of TILs. Across the independent claims, the core inventive theme is combining demethylation or epigenetic modulation of STING with STING agonist-driven enhancement of tumor-cell antigenicity to generate enhanced TILs.

Demethylating tumor cells and culturing with a STING agonist to enhance TIL generation

A method for producing enhanced tumor infiltrating lymphocytes (TILs) comprising culturing tumor cells from a subject in the presence of a demethylating agent and a STING agonist and co-culturing TILs with these treated tumor cells and further expanding the TILs after their exposure.

Demethylating a subject to increase STING expression, then culturing tumor cells with a STING agonist to increase antigenicity before co-culture with TILs

A method for producing enhanced tumor infiltrating lymphocytes (TILs) comprising treating a subject with an effective amount of a demethylating agent to increase STING expression in tumor cells of the subject; isolating tumor cells from the subject; culturing the tumor cells in the presence of a STING agonist in an amount effective to increase the antigenicity of the tumor cells; and co-culturing TILs with these treated tumor cells and further expanding the TILs after their exposure.

Both independent claims cover producing enhanced TILs by combining demethylation to increase or demethylate STING proteins or increase STING expression with a STING agonist to support increased antigenicity, followed by co-culture and further expansion of TILs after exposure to the treated tumor cells.

Stated Advantages

Restores or increases STING-dependent signaling and tumor-cell immune engagement, including induction of CXCL10 and IFN-β and increased MHC-I (HLA-A/B/C) expression.

Enhances HLA-restricted TIL effector functions, including IFN-γ release and cytotoxicity.

Links STING activation to tumor immune cell recruitment through CXCR3-binding chemokines.

Documented Applications

Melanoma-focused methods to enhance antitumor T-cell responses by increasing tumor-cell STING and/or cGAS signaling and producing enhanced TILs.

Application to melanoma cell lines with defective STING signaling and to approaches that assess STING/cGAS expression and DNA methylation in tumor biopsies.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.